SCHEMBL4714569

SCHEMBL4714569

Cc1ccc(O)c(/C=C/c2cccc(F)c2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.58
NQO2 P16083 1/20 0.58
NFE2L2 Q16236 10/20 0.53
PTGS2 P35354 1/20 0.51
RELA Q04206 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
APP P05067 3/20 0.45
GLO1 Q04760 1/20 0.43
GRM4 Q14833 1/20 0.43
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714571 1.00 PTGS1 (0.58) PTGS1NQO2NFE2L2PTGS2RELA
SCHEMBL27497604 0.84 PTGS1 (0.47) PTGS1NQO2NFE2L2PTGS2RELA
SCHEMBL4711845 0.82 CHAT (0.45) RELAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4711844 0.82 CHAT (0.45) RELAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL27497603 0.81 PTGS1 (0.48) PTGS1NQO2NFE2L2PTGS2RELA
SCHEMBL4712775 0.81 GRM4 (0.51) PTGS1PTGS2KDM4ENPC1ALDH1A1
SCHEMBL4710346 0.81 GRM4 (0.51) PTGS1PTGS2KDM4ENPC1ALDH1A1
SCHEMBL4710348 0.81 GRM4 (0.51) PTGS1PTGS2KDM4ENPC1ALDH1A1
SCHEMBL4714568 0.76 NFE2L2 (0.44) PTGS1NQO2NFE2L2PTGS2RELA
SCHEMBL4714566 0.76 NFE2L2 (0.44) PTGS1NQO2NFE2L2PTGS2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-0998459-A2 PYRIDINE DERIVATIVES Novartis AG (CH) 2000-05-10 EP claimed
WO-1999002497-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 1999-01-21 WO claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed